Signal Advisors Wealth LLC Makes New Investment in Danaher Corporation $DHR

Key Points

• Signal Advisors Wealth acquired 6,587 Danaher shares worth approximately $1.46 million in the third quarter, while institutional investors collectively own 79.05% of the company.
• Analysts maintain a generally positive outlook, with Danaher receiving a consensus “Moderate Buy” rating and an average price target of $235.41; recent targets range from $220 to $255.
• Danaher reported quarterly EPS of $1.94, exceeding estimates, while revenue rose 5.5% year over year to $6.26 billion. The company also declared a quarterly dividend of $0.40 per share, yielding approximately 0.7%.

Signal Advisors Wealth LLC acquired a new stake in Danaher Corporation (NYSE:DHR - Free Report) during the third quarter, according to its most recent disclosure with the SEC. The institutional investor acquired 6,587 shares of the conglomerate's stock, valued at approximately $1,459,000.

A number of other hedge funds and other institutional investors also recently modified their holdings of DHR. GEM Asset Management LLC acquired a new position in shares of Danaher in the third quarter valued at about $937,000. Copeland Capital Management LLC acquired a new position in shares of Danaher during the 3rd quarter worth approximately $773,000. Foster Group Inc. acquired a new position in shares of Danaher during the 3rd quarter worth approximately $716,000. B. Riley Wealth Advisors Inc. bought a new position in shares of Danaher during the third quarter worth approximately $3,054,000. Finally, Krilogy Financial LLC increased its holdings in shares of Danaher by 104.2% during the third quarter. Krilogy Financial LLC now owns 23,336 shares of the conglomerate's stock worth $5,170,000 after purchasing an additional 11,906 shares during the period. Institutional investors and hedge funds own 79.05% of the company's stock.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Stifel Nicolaus reduced their price target on Danaher from $260.00 to $220.00 and set a "buy" rating on the stock in a research report on Wednesday, July 22nd. Morgan Stanley lifted their price objective on Danaher from $220.00 to $240.00 and gave the company an "overweight" rating in a report on Monday. TD Cowen lifted their price objective on Danaher from $236.00 to $255.00 and gave the company a "buy" rating in a report on Tuesday. Guggenheim upped their target price on Danaher from $200.00 to $250.00 and gave the company a "buy" rating in a research report on Thursday, October 1st. Finally, Deutsche Bank Aktiengesellschaft reissued a "buy" rating and set a $240.00 target price on shares of Danaher in a report on Wednesday, July 22nd. Two research analysts have rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and four have assigned a Hold rating to the company's stock. Based on data from MarketBeat, Danaher has an average rating of "Moderate Buy" and a consensus price target of $235.41.

Danaher Price Performance

DHR stock opened at $224.65 on Thursday. The company has a quick ratio of 1.25, a current ratio of 1.65 and a debt-to-equity ratio of 0.48. Danaher Corporation has a 12 month low of $160.93 and a 12 month high of $242.80. The firm has a market cap of $157.93 billion, a P/E ratio of 39.90, a P/E/G ratio of 2.80 and a beta of 0.76. The company's 50-day moving average price is $212.92 and its two-hundred day moving average price is $195.39.

Danaher (NYSE:DHR - Get Free Report) last issued its earnings results on Monday, July 20th. The conglomerate reported $1.94 EPS for the quarter, beating the consensus estimate of $1.85 by $0.09. Danaher had a net margin of 15.95% and a return on equity of 11.04%. The company had revenue of $6.26 billion during the quarter, compared to analysts' expectations of $6.12 billion. During the same period in the previous year, the company earned $0.77 EPS. The business's revenue for the quarter was up 5.5% compared to the same quarter last year. On average, analysts anticipate that Danaher Corporation will post 8.53 earnings per share for the current fiscal year.

Danaher Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.40 dividend. This represents a $1.60 dividend on an annualized basis and a yield of 0.7%. The ex-dividend date of this dividend is Wednesday, September 30th. Danaher's dividend payout ratio (DPR) is 28.42%.

Trending Headlines about Danaher

Here are the key news stories impacting Danaher this week:

• Positive Sentiment: AI partnership with NVIDIA: Danaher announced a collaboration to combine its scientific instruments, laboratory automation, workflow software and industry expertise with NVIDIA’s accelerated computing and AI technologies. The initiative is intended to advance autonomous science and speed scientific discovery, supporting Danaher’s long-term growth outlook in life-science tools and laboratory automation. Danaher Collaborates with NVIDIA to Advance Autonomous Science
• Positive Sentiment: Potential earnings beat: Zacks reports that Danaher has a strong history of exceeding quarterly estimates and currently has favorable Earnings ESP and consensus-estimate trends, raising expectations for another beat in its upcoming report. The company previously exceeded estimates with quarterly earnings of $1.94 per share versus a $1.85 consensus, while revenue rose 5.5% year over year. Will Danaher Beat Estimates Again in Its Next Earnings Report?
• Positive Sentiment: Longer-term automation opportunity: Danaher’s planned AI-powered autonomous laboratory, targeted for commercial-scale operation in early 2027, gives investors a potential future growth catalyst. The NVIDIA relationship could strengthen Danaher’s position as laboratories adopt AI and physical automation. How to Invest in AI Drug Discovery
• Neutral Sentiment: Analyst support: Morgan Stanley maintained a $240 price target, implying continued confidence in Danaher’s prospects, although the unchanged target provides no new upgrade catalyst. Morgan Stanley Keeps $240 Target for Danaher Stock
• Neutral Sentiment: Board changes: Danaher expanded its board to 13 members and appointed new directors, a governance development with limited immediate earnings or valuation impact. Danaher Enhances Board With New Director Appointments

About Danaher

Danaher Corporation NYSE: DHR is a global science and technology company that develops and manufactures products, services and solutions for the life sciences, diagnostics and biotechnology industries. Its offerings help researchers, healthcare professionals and biopharmaceutical manufacturers discover, develop, produce and analyze medicines and other biological products.

The company operates through businesses that provide laboratory instruments, consumables, software and services, including technologies for cell analysis, genomics, protein research, bioprocessing and clinical diagnostics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.